Toronto, Ontario--(Newsfile Corp. - Le 19 mars/March 2024) - PanGenomic Health Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every ten (10) pre-consolidated common shares.
As a result, the outstanding shares of the company will be reduced to approximately 10,496,746 common shares.
The name and symbol will not change.
Please note that all open orders will be canceled at the close of business on March 20, 2024. Dealers are reminded to re-enter their orders taking into account the share consolidation.
_________________________________
PanGenomic Health Inc. a annoncé une consolidation de ses actions ordinaires émises et en circulation sur la base d'une (1) action ordinaire post-consolidée pour dix (10) actions ordinaires pré-consolidées.
En conséquence, les actions en circulation de la société seront réduites à environ 10 496 746 actions ordinaires.
Le nom et le symbole ne changeront pas.
Veuillez noter que toutes les commandes ouvertes seront annulées à la fermeture des bureaux le 20 mars 2024. Il est rappelé aux concessionnaires de ré-saisir leurs commandes en tenant compte de la consolidation des actions.
Trading on a Consolidated Basis/Négociation sur une Base Consolidée : | Le 21 mars/March 2024 |
Record Date/Date d’Enregistrement : | Le 22 mars/March 2024 |
Anticipated Payment Date/Date de Paiement Prévue : | Le 22 mars/March 2024 |
Symbol/Symbole : | NARA |
NEW/NOUVEAU CUSIP : | 69842E 30 4 |
NEW/NOUVEAU ISIN : | CA 69842E 30 4 1 |
Old/Vieux CUSIP & ISIN : | 69842E205/CA69842E2050 |
If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it..
Pour toute question ou information complémentaire, veuillez contacter Listings au 416 367-7340 ou par courriel à: This email address is being protected from spambots. You need JavaScript enabled to view it..
Last Trade: | C$0.16 |
Daily Volume: | 0 |
Market Cap: | C$1.020M |
December 31, 2024 February 16, 2024 January 09, 2024 December 06, 2023 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load